Progress and Perspectives on HIV-1 microbicide development (Q26739967)

Europe PubMed Central

title

Progress and Perspectives on HIV-1 microbicide development (English)

0 references

author name string

Kabamba B Alexandre

1

0 references

Hazel T Mufhandu

2

0 references

Grace M London

3

0 references

E Chakauya

4

0 references

M Khati

5

0 references

language of work or name

English

0 references

publication date

15 July 2016

0 references

number of pages

12

1 reference

Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?

inferred from page(s)

published in

Virology

0 references

volume

497

0 references

page(s)

69-80

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Comparison of vaginal aminopeptidase enzymatic activities in various animals and in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal concentrations of lactic acid potently inactivate HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Coaxially electrospun fiber-based microbicides facilitate broadly tunable release of maraviroc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Drug-eluting fibers for HIV-1 inhibition and contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

ACIDFORM: a review of the evidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

In vivo identification of Langerhans and related dendritic cells infected with HIV-1 subtype E in vaginal mucosa of asymptomatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Electrospun fibers for vaginal anti-HIV drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

No increase in cervicovaginal proinflammatory cytokines after Carraguard use in a placebo-controlled randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Aptamers come of age - at last

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Recent observations on HIV type-1 infection in the genital tract of men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal microbicides and the prevention of HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Gels as vaginal drug delivery systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Langerin is a natural barrier to HIV-1 transmission by Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Development of dapivirine vaginal ring for HIV prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

The plasma membrane as a combat zone in the HIV battlefield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

In vitro selection of RNA molecules that bind specific ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Setting the stage: host invasion by HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Bridging efficient viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Sensitivity Analysis of a Pharmacokinetic Model of Vaginal Anti-HIV Microbicide Drug Delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Distribution of lymphocytes and adhesion molecules in human cervix and vagina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Retroviral spread by induction of virological synapses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Human immunodeficiency virus type 1 assembly, budding, and cell-cell spread in T cells take place in tetraspanin-enriched plasma membrane domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Significant virus replication in Langerhans cells following application of HIV to abraded skin: relevance to occupational transmission of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2′F-RNA Aptamers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cellular cholesterol efflux mediated by cyclodextrins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Microbicides and other topical strategies to prevent vaginal transmission of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

CCR5 inhibitors: emergence, success, and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

HIV binding, penetration, and primary infection in human cervicovaginal tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Advances in microbicide vaginal rings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Tenofovir-based preexposure prophylaxis for HIV infection among African women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Progesterone implants enhance SIV vaginal transmission and early virus load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Development of a multi-layered vaginal tablet containing dapivirine, levonorgestrel and acyclovir for use as a multipurpose prevention technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Recruitment of HIV and its receptors to dendritic cell-T cell junctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Target cells in vaginal HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Aptamers: an emerging class of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

HIV entry inhibitors in clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Dangerous liaisons at the virological synapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

DC-SIGN and DC-SIGNR: helping hands for HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Current and future microbicide approaches aimed at preventing HIV infection in women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Chemokine receptor expression on mucosal dendritic cells from the endocervix of healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Drivers of Vaginal Drug Delivery System Acceptability from Internet-Based Conjoint Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Aptamers--basic research, drug development, and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cost-effective production of a vaginal protein microbicide to prevent HIV transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Microbicide research: current and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Vaginal drug delivery systems for HIV prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Formulation development of retrocyclin 1 analog RC-101 as an anti-HIV vaginal microbicide product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

NOX2 Controls Phagosomal pH to Regulate Antigen Processing during Crosspresentation by Dendritic Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Male tolerance of ACIDFORM gel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Inhibiting sexual transmission of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Aptamer-based therapeutics: new approaches to combat human viral diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Estrogen protects against vaginal transmission of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Prostaglandin E2 vaginal gel or tablets for the induction of labour at term: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Enhancement of HIV infection by cellulose sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

SELMA: Selection with Modified Aptamers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

7 January 2021

Langerhans' cells and lymphocyte subsets in the female genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

7 January 2021

Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

7 January 2021

Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

7 January 2021

Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2016.07.004

7 January 2021